Eli Lilly Stock (LLY): $280 Price Target From Wells Fargo

By Amit Chowdhry ● Jan 10, 2022
  • The shares of Eli Lilly And Co (NYSE: LLY) have received a $280 price target from Wells Fargo. These are the details.

The shares of Eli Lilly And Co (NYSE: LLY) have received a $280 price target from Wells Fargo. And Wells Fargo analyst Mohit Bansal is maintaining an “Equal-Weight” rating on the company shares.

Bansal increased the price target on Eli Lilly from $270 to account for the $800 million higher expectations for the Obesity franchise. And Bansal believes that Biogen’s decision to cut Alzheimer’s drug Aduhelm pricing could put a cap on anti-Amyloid medicine pricing. 

But Bansal also noted that both BAN-2401 and Donanemab can be priced slightly higher versus Aduhelm upon the Phase 3 success. And there could be a $9 billion-$11 billion peak unadjusted opportunity for each of these meds as incremental access will likely offset lower price.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.